Lilly Hits $1 Trillion Valuation on 56% Revenue Surge and 47% Margin
LLY•Lilly’s stock has gained 54% over nine months, pushing its market value past $1 trillion on the back of incretin franchises. Quarterly revenue grew 56% year-over-year with Mounjaro and Zepbound sales of $12.8 billion and operating margins rising to 47.3%.
1. Rapid Stock Repricing Delivers $1 Trillion Valuation
Over the past nine months, Lilly’s share price climbed 54%, driving its market capitalization above $1 trillion—a fundamental repricing driven by exceptional sales growth rather than a market bounce. This surge outpaced the S&P 500’s 15% return and reflects investor confidence in Lilly’s growth trajectory.
2. Incretin Franchise Powers Revenue and Margins
Quarterly revenue rose 56% year-over-year, propelled by combined Mounjaro and Zepbound sales of $12.8 billion, while operating margins jumped to a record 47.3%. These figures significantly exceed the company’s three-year averages of 37.9% growth and 35.3% margin, underscoring high profitability from the incretin portfolio.
3. New Obesity Pill and Pipeline Acquisitions
FDA approval of the oral weight-management pill Foundayo positions Lilly at the forefront of the obesity market, marking the first incretin launched for obesity indication. Concurrent biotech acquisitions, including Orna Therapeutics and Centessa Pharmaceuticals, aim to expand the pipeline and sustain long-term growth.
